- category:Pipeline
Pipeline
Eyenovia and Senju to develop chronic dry eye drop-device combo
Collaboration features the Optejet dosing delivery system delivering a corneal epithelial wound healing-ophthalmic solution.
Pipeline
Beacon Therapeutics to evaluate patented AAV gene therapy for retinal diseases
Licensing agreement involves potential development and commercialization of Abeona Therapeutics’ patented capsid, a pan-retinal-administered vector.
Pipeline
Beacon Therapeutic raises $170M for XLRP gene therapy development
Funding supports clinical trials on AGTC-501, lead asset designed to address all photoreceptor damage caused by XLRP.
Pipeline
Ocugen doses first patient in phase 3 RP gene therapy trial
Prior clinical data supports OCU400 in improving baseline vision among patients with RP associated RHO and N2ER3 mutations.
Pipeline
FDA clears 4DMT's IND for genetic GA treatment
Novel genetic medicine is formulated as a proprietary low-dose intravitreal AAV vector with plans for phase 1 clinical trial initiation expected in H2 2024.
Pipeline
Neurotech Pharma earns BLA priority review for MacTel cell therapy
Investigational ocular implant is designed to slow progression of gradual central vision deterioration in rare neurodegenerative retinal disease.
Pipeline
FDA grants Breakthrough Therapy Designation, RMAT to Aurion's CED cell therapy
AURN001 is now the first allogeneic cell therapy to be granted two designations for corneal edema secondary to CED.
Pipeline
J&J reports significant phase 2 data in nipocalimab for Sjögren's disease
Dose-ranging study on monoclonal antibody notes improvement trends for key symptoms of dry eye disease.
Pipeline
Viridian to initiate two phase 3 studies for chronic TED
VRDN-003, an IGF-IR monoclonal antibody, will be evaluated as a subcutaneous injection administered every 4 or 8 weeks.
Pipeline
Ocular Therapeutix releases positive NPDR phase 1 data, plans for wet AMD repeat dosing study
Updates follow company’s decision to cut 13% of workforce in order to focus on the clinical development of axitinib intravitreal implant.
Pipeline
Enrollment concludes in phase 3 reproxalap trial for DED
Pending positive data outcomes, Aldeyra plans to resubmit a new drug application to the FDA for the RASP inhibitor eye drop.
Pipeline
Skye shifting away from eye care after phase 2 glaucoma study fails
Clinical trial evaluating SBI-100 OE did not achieve statistical significance in improving IOP for patients with POAG and OHT.
Pipeline
Beacon Therapeutics doses first patient in VISTA XLRP gene therapy trial
Randomized study is investigating AGTC-501 for the treatment of patients diagnosed with x-linked retinitis pigmentosa.
Pipeline
Oculis reports positive phase 2b topline data on licaminlimab for DED
OSC-02 eye drop demonstrates rapid treatment effect on corneal inflammation as early as 2 weeks of treatment.
Pipeline
First patient dosed in phase 3 study on needle- and opioid-free sedation for cataract surgery
Melt Pharmaceuticals’ rapid-dissolving tablet intends to offer greater patient comfort during sedation without the need for needles or opioids.
Pipeline
First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001
New study on selenium sulfide ointment follows positive phase 2 data supporting its ability to target the pathophysiology of MGD.
Pipeline
Drug Farm receives FDA IND clearance for ROSAH syndrome candidate
ALPK1 selective kinase inhibitor is the first therapeutic to target the genetic cause of this rare disease.
Pipeline
Dopavision reports topline data in photobiomodulation myopia trial
Virtual reality-based app provides a non-invasive method for possibly increasing dopamine levels in the retina to mitigate and manage the disease.
Pipeline
HanAll Biopharma kicks off phase 3 DED trial on topical anti-inflammatory
VELOS-4 trial is evaluating tanfanerept for improvement in Schirmer test following last year’s phase 3 primary endpoint miss.
Pipeline